HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.

AbstractPURPOSE:
Tumor-initiating cells with stem-like properties, also termed cancer stem cells (CSC), have been shown to sustain tumor growth as well as metastasis and are highly resistant to chemotherapy. Because pancreatic CSCs have been isolated on the basis of EpCAM expression, we investigated whether a targeted immunotherapy to EpCAM using the bispecific T-cell-engaging antibody MT110 is capable of eradicating CSCs.
EXPERIMENTAL DESIGN:
We studied in vitro and in vivo the effects of MT110 on CSCs using both established cell lines as well as primary cells of human pancreatic cancer.
RESULTS:
Although established cell lines were more responsive to MT110-engaged T cells, also primary cells showed a time- and dose-dependent response to treatment with the bispecific antibody. In addition, the population of highly tumorigenic CSCs was efficiently targeted by the EpCAM/CD3-bispecific antibody MT110 in vitro and in vivo using a mouse model of established primary pancreatic cancer. Pancreatic cancer cells derived from metastases were slightly more resistant to MT110 treatment on the basis of in vivo tumorigenicity studies. This appeared to be related to a higher frequency of an EpCAM-negative subpopulation of CSCs.
CONCLUSIONS:
Cytotoxic T cells can be effectively redirected against primary human pancreatic cancer cells by T-cell-engaging BiTE antibody MT110 including a subpopulation of highly tumorigenic CSCs.
AuthorsMichele Cioffi, Jorge Dorado, Patrick A Baeuerle, Christopher Heeschen
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 18 Issue 2 Pg. 465-74 (Jan 15 2012) ISSN: 1557-3265 [Electronic] United States
PMID22096026 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2011 AACR.
Chemical References
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD3 Complex
  • Cell Adhesion Molecules
  • EPCAM protein, human
  • Epithelial Cell Adhesion Molecule
  • MT110 monoclonal antibody
  • Single-Chain Antibodies
Topics
  • Animals
  • Antibody-Dependent Cell Cytotoxicity (drug effects)
  • Antigens, Neoplasm (immunology, metabolism)
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • CD3 Complex (immunology, metabolism)
  • CD8-Positive T-Lymphocytes (drug effects, immunology)
  • Cell Adhesion Molecules (immunology, metabolism)
  • Cell Survival (drug effects)
  • Coculture Techniques
  • Epithelial Cell Adhesion Molecule
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Neoplastic Stem Cells (drug effects, immunology, metabolism)
  • Pancreatic Neoplasms (drug therapy)
  • Primary Cell Culture
  • Single-Chain Antibodies (pharmacology, therapeutic use)
  • Spheroids, Cellular (drug effects)
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: